Goldman Sachs
TARS icon

Goldman Sachs’s Tarsus Pharmaceuticals TARS Stock Holding History

Goldman Sachs’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46.7M Buy
742,693
+303,067
+69% +$19.4M ﹤0.01% 1868
2026
Q1 		$30.8M Buy
439,626
+60,922
+16% +$4.26M ﹤0.01% 2029
2025
Q4 		$31M Buy
378,704
+37,692
+11% +$2.81M ﹤0.01% 1945
2025
Q3 		$20.3M Sell
341,012
-56,982
-14% -$2.81M ﹤0.01% 2255
2025
Q2 		$16.1M Buy
397,994
+96,484
+32% +$4.34M ﹤0.01% 2325
2025
Q1 		$15.5M Sell
301,510
-17,220
-5% -$851K ﹤0.01% 2278
2024
Q4 		$17.6M Buy
318,730
+49,955
+19% +$2.27M ﹤0.01% 2253
2024
Q3 		$8.84M Buy
268,775
+63,224
+31% +$1.78M ﹤0.01% 2844
2024
Q2 		$5.59M Buy
205,551
+1,821
+0.9% +$61.2K ﹤0.01% 3050
2024
Q1 		$7.41M Sell
203,730
-33,709
-14% -$991K ﹤0.01% 2755
2023
Q4 		$4.81M Buy
237,439
+137,377
+137% +$2.29M ﹤0.01% 3192
2023
Q3 		$1.78M Buy
100,062
+23,110
+30% +$409K ﹤0.01% 3857
2023
Q2 		$1.39M Buy
76,952
+48,387
+169% +$769K ﹤0.01% 4126
2023
Q1 		$359K Sell
28,565
-27,103
-49% -$396K ﹤0.01% 5015
2022
Q4 		$816K Sell
55,668
-53,060
-49% -$878K ﹤0.01% 4561
2022
Q3 		$1.86M Buy
108,728
+10,018
+10% +$159K ﹤0.01% 4041
2022
Q2 		$1.44M Buy
98,710
+70,454
+249% +$1.06M ﹤0.01% 4328
2022
Q1 		$475K Buy
28,256
+153
+0.5% +$2.84K ﹤0.01% 5349
2021
Q4 		$632K Buy
28,103
+1,623
+6% +$42.2K ﹤0.01% 5208
2021
Q3 		$571K Sell
26,480
-400
-1% -$9.9K ﹤0.01% 5116
2021
Q2 		$779K Sell
26,880
-2,114
-7% -$66K ﹤0.01% 4944
2021
Q1 		$934K Buy
+28,994
New +$1.07M ﹤0.01% 4670

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Goldman Sachs's TARS Position: Q2 2026 in Review

Goldman Sachs increased its Tarsus Pharmaceuticals (TARS) stake by 69% in Q2 2026, buying an estimated $19.4M and bringing the position to 742,693 shares worth $46.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1868.

Goldman Sachs first reported a position in TARS in Q1 2021 and has held it in 22 quarters since. 256 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Goldman Sachs held 742,693 shares of Tarsus Pharmaceuticals worth $46.7M as of Q2 2026.
  • Goldman Sachs bought 303,067 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $19.4M.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #1868 holding.
  • Goldman Sachs first reported a position in Tarsus Pharmaceuticals in Q1 2021 and has held it in 22 quarters since.
  • 256 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.